Cargando…

Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy

OBJECTIVES: The objective of the study is to assess the clinical, immunological, and virological outcomes in treatment-experienced HIV patients on raltegravir (RAL)-based salvage therapy. METHODS: This was a retrospective, observational study of patients with suspected second-line antiretroviral the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshwal, Rajesh, Arora, Sumit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532488/ https://www.ncbi.nlm.nih.gov/pubmed/31143859 http://dx.doi.org/10.4103/ijstd.IJSTD_23_18

Ejemplares similares

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2017)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Study of clinical profile and outcomes in progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome patients in the highly active antiretroviral therapy era – An observational study
por: Arora, Sumit, et al.
Publicado: (2022)

Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting
por: Chehadeh, Wassim, et al.
Publicado: (2020)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
por: Hall, Nolwenn, et al.
Publicado: (2022)

Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China
por: Zheng, Junwen, et al.
Publicado: (2014)

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Bunnell, Kristen L., et al.
Publicado: (2018)

Virologic and immunologic effectiveness of darunavir-based salvage therapy in HIV-1-infected adults in a Brazilian clinical practice setting: results of a multicenter and retrospective cohort study
por: Ribeiro, Karina Mota, et al.
Publicado: (2013)

2487. Low Rate of Virologic Failure in Antiretroviral Experienced Patients Prescribed Once Daily Raltegravir
por: Hsu, Ricky, et al.
Publicado: (2019)

Long-term clinical, immunological and virological outcomes of patients on antiretroviral therapy in southern Myanmar
por: Bermúdez-Aza, Elkin Hernán, et al.
Publicado: (2018)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
por: Charpentier, Charlotte, et al.
Publicado: (2010)

Stable HIV-1 integrase diversity during initial HIV-1 RNA Decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy
por: Noguera-Julian, Marc, et al.
Publicado: (2013)

Immunological and virologic outcomes of people living with HIV in Guangxi, China: 2012-2017
por: Yang, Xueying, et al.
Publicado: (2019)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy
por: Prabhakar, B., et al.
Publicado: (2011)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Immunological and virological aspects of HIV cell-to-cell transfer
por: Schwartz, Olivier
Publicado: (2009)

Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV–HCV coinfected patients
por: Emery, Joel, et al.
Publicado: (2010)

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens
por: Cozzi‐Lepri, A, et al.
Publicado: (2017)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Virology and Immunology of Bats
por: Schountz, Tony
Publicado: (2013)

Long‐term clinical, virological and immunological outcomes following planned treatment interruption in HIV‐infected children
por: Freguja, R, et al.
Publicado: (2020)

HIV post-treatment controllers have distinct immunological and virological features
por: Etemad, Behzad, et al.
Publicado: (2023)

Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
por: Tukei, Vincent J, et al.
Publicado: (2013)

Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
por: Jacobs, Tom G., et al.
Publicado: (2022)

Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands
por: Van Den Hof, Malon, et al.
Publicado: (2023)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
por: Bercoff, Danielle Perez, et al.
Publicado: (2010)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ol89dugebd2pldhj6qvqaor38b